Literature DB >> 2565823

Glycolysis in P-glycoprotein-overexpressing human tumor cell lines. Effects of resistance-modifying agents.

H J Broxterman1, H M Pinedo, C M Kuiper, G J Schuurhuis, J Lankelma.   

Abstract

We show that drugs, such as verapamil, which reverse multidrug resistance (MDR), in P-glycoprotein-overexpressing tumor cells, increased the rate of lactate production in four human MDR cell lines, but not in the parent, sensitive cell lines. The effect on glycolytic rate was maximal at a medium concentration of 2 microM verapamil. The glycolytic rate in sensitive (A2780) and MDR 2780AD) cells showed the same pH dependence, but the effect of verapamil was seen only in 2780AD cells at all pH values investigated (6.6, 7.4 and 8.2). A series of drugs such as nigericin, oligomycin, amiloride and monensin had similar effects in the two cells. Phorbol myristate acetate increased lactate formation in neither cell line. Verapamil induced an extra amount of ATP consumption in P-glycoprotein-expressing 2780AD cells of approx. 25 pmol/s per 10(6) cells, which was estimated to be about 10% of cellular energy turnover.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565823     DOI: 10.1016/0014-5793(89)81380-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges".

Authors:  Yoonseok Kam; Tuhin Das; Haibin Tian; Parastou Foroutan; Epifanio Ruiz; Gary Martinez; Susan Minton; Robert J Gillies; Robert A Gatenby
Journal:  Int J Cancer       Date:  2014-09-02       Impact factor: 7.396

2.  Evolutionary approaches to prolong progression-free survival in breast cancer.

Authors:  Ariosto S Silva; Yoonseok Kam; Zayar P Khin; Susan E Minton; Robert J Gillies; Robert A Gatenby
Journal:  Cancer Res       Date:  2012-10-12       Impact factor: 12.701

Review 3.  Evolutionary strategy for systemic therapy of metastatic breast cancer: balancing response with suppression of resistance.

Authors:  Yoonseok Kam; Tuhin Das; Susan Minton; Robert A Gatenby
Journal:  Womens Health (Lond)       Date:  2014-07

Review 4.  Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?

Authors:  Francisco S Chung; Jayson S Santiago; Miguel Francisco M De Jesus; Camille V Trinidad; Melvin Floyd E See
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

5.  In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.

Authors:  Teréz Márián; Gábor Szabó; Katalin Goda; Henrietta Nagy; Nóra Szincsák; István Juhász; László Galuska; László Balkay; Pál Mikecz; Lajos Trón; Zoltán Krasznai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-27       Impact factor: 9.236

Review 6.  Is resistance useless? Multidrug resistance and collateral sensitivity.

Authors:  Matthew D Hall; Misty D Handley; Michael M Gottesman
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

7.  Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.

Authors:  Chaojun Xue; Changyuan Wang; Qi Liu; Qiang Meng; Huijun Sun; Xiaokui Huo; Xiaodong Ma; Zhihao Liu; Xiaochi Ma; Jinyong Peng; Kexin Liu
Journal:  Tumour Biol       Date:  2016-01-06

Review 8.  Glutathione-related enzymes, glutathione and multidrug resistance.

Authors:  J A Moscow; K H Dixon
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

9.  Cost, effectiveness and environmental relevance of multidrug transporters in sea urchin embryos.

Authors:  Bryan J Cole; Amro Hamdoun; David Epel
Journal:  J Exp Biol       Date:  2013-08-02       Impact factor: 3.312

10.  Variable Cell Line Pharmacokinetics Contribute to Non-Linear Treatment Response in Heterogeneous Cell Populations.

Authors:  Matthew T McKenna; Jared A Weis; Vito Quaranta; Thomas E Yankeelov
Journal:  Ann Biomed Eng       Date:  2018-02-26       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.